ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 954,48
1,85%
DAX
18 518,03
-0,44%
Brent Oil
83,35
-1,17%
Bitcoin
64 751,29
-0,15%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
07/01/202013h00GlobeNewswire Inc.Summit Therapeutics Launches Online Resource for Patients with C. difficile InfectionNASDAQ:SMMTSummit Therapeutics Inc
02/01/202022h40Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:SMMTSummit Therapeutics Inc
27/12/201922h32Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SMMTSummit Therapeutics Inc
23/12/201922h06Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
17/12/201913h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 Octobe...NASDAQ:SMMTSummit Therapeutics Inc
16/12/201915h15GlobeNewswire Inc.Notice of Q3 ResultsNASDAQ:SMMTSummit Therapeutics Inc
06/12/201922h33Edgar (US Regulatory)Amended Report of Foreign Issuer (6-k/a)NASDAQ:SMMTSummit Therapeutics Inc
06/12/201913h24GlobeNewswire Inc.Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General MeetingNASDAQ:SMMTSummit Therapeutics Inc
06/11/201913h00GlobeNewswire Inc.Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance CongressNASDAQ:SMMTSummit Therapeutics Inc
04/11/201913h00GlobeNewswire Inc.Summit Therapeutics Recognises C. difficile Awareness MonthNASDAQ:SMMTSummit Therapeutics Inc
16/10/201913h00GlobeNewswire Inc.Summit Therapeutics to Present at the 2019 BIO Investor ForumNASDAQ:SMMTSummit Therapeutics Inc
11/10/201913h00GlobeNewswire Inc.Half-year reportNASDAQ:SMMTSummit Therapeutics Inc
10/10/201915h30GlobeNewswire Inc.Notice of ResultsNASDAQ:SMMTSummit Therapeutics Inc
07/10/201913h00GlobeNewswire Inc.Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Impro...NASDAQ:SMMTSummit Therapeutics Inc
03/10/201913h00GlobeNewswire Inc.Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients wi...NASDAQ:SMMTSummit Therapeutics Inc
01/10/201916h07PR Newswire (US)Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019NASDAQ:SMMTSummit Therapeutics Inc
25/09/201913h00GlobeNewswire Inc.Summit Therapeutics to Host R&D Day 7 October 2019NASDAQ:SMMTSummit Therapeutics Inc
24/09/201913h00GlobeNewswire Inc.Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019NASDAQ:SMMTSummit Therapeutics Inc
18/09/201908h00GlobeNewswire Inc.Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive...NASDAQ:SMMTSummit Therapeutics Inc
05/09/201913h00GlobeNewswire Inc.Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID ConferenceNASDAQ:SMMTSummit Therapeutics Inc
04/09/201913h00GlobeNewswire Inc.Summit Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SMMTSummit Therapeutics Inc
01/08/201913h00GlobeNewswire Inc.Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceNASDAQ:SMMTSummit Therapeutics Inc
17/07/201913h00GlobeNewswire Inc.Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World CongressNASDAQ:SMMTSummit Therapeutics Inc
09/07/201913h00GlobeNewswire Inc.Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and PneumoniaNASDAQ:SMMTSummit Therapeutics Inc
01/07/201915h13PR Newswire (US)X-Biotix Therapeutics Joins Antimicrobials Working GroupNASDAQ:SMMTSummit Therapeutics Inc
21/06/201922h21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SMMTSummit Therapeutics Inc
21/06/201912h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SMMTSummit Therapeutics Inc
20/06/201917h13PR Newswire (US)Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019NASDAQ:SMMTSummit Therapeutics Inc
20/06/201913h00GlobeNewswire Inc.Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019NASDAQ:SMMTSummit Therapeutics Inc
18/06/201913h00GlobeNewswire Inc.Increased BARDA Award and Option ExerciseNASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

BOV
EZTCG146
EZTCG146 Ex:14,6
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés